Palliative radiation therapy for patients with large or resistant tumors
Official title: Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Run by Sir Mortimer B. Davis - Jewish General Hospital · NCT02333110 · Data updated 2026-11-12
This study is testing a new type of radiation therapy to see if it can help relieve symptoms for patients with large or hard-to-treat tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | January 2015 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT02333110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with confirmed malignancies and bulky tumors or tumors known to be resistant to radiation.
✕Probably not a fit
Patients with potentially curable tumors or those who have previously received palliative radiation with hypofractionation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of spatially fractionated radiation therapy (SFR) as a palliative treatment for patients with symptomatic bulky tumors larger than 8 cm or tumors resistant to traditional radiation. The approach aims to deliver a single treatment using a grid technique, which may reduce the toxicity and logistical burden associated with conventional multi-fraction radiation therapy. Patients will be monitored for safety and efficacy in alleviating symptoms related to their tumors. The study is conducted at the Jewish General Hospital in Montreal.
Why it matters
Potential benefit: If successful, this treatment could provide significant symptom relief for patients with large or radioresistant tumors while minimizing treatment-related side effects.
How similar studies have gone: While the use of spatially fractionated radiation is a novel approach, similar studies have shown promise in reducing treatment burden and improving patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible. * Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation * Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis * WHO performance status of 0-2 * Aged 18 years or older * Ability to sign and understand an informed consent form Exclusion Criteria: * Potentially curable patient * Previous palliative radiation with hypofractionation * Tumor located near the spinal cord or in the brain * Pregnant or nursing woman
Where it's running
-
Sir Mortimer Jewish General Hospital
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Te Vuong, MD — Sir Mortimer Jewish General Hospital
- Study coordinator: Luciana Poggi, PhD
- Email: luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca
- Phone: 514-340-8222
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.